Therefore, it must be taken into account that GCs may not only contribute to suppress recognition of tumours expressing PD-Ls, but may even reduce the efficacy of immunotherapy targeting the PD-1/PD-L1 pathway. The gene discussed is PDCD1; the disease is neoplasm.